Ad
Thursday, 3 August 2017
Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline
(Reuters) - Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment